COVID-19 Records

Gates Package — page 865

of 1375 pages

← p.864 p.866 → · this page in the original PDF · package

From: To: "Collins, Francis (NIH/NHGRI) [E]" HE ont. gov> "Dieffenbach, Carl (NIH/NIAID) [E]" [EEE Oniaid.nih.gov>, "Gibbons, Gary (NIH/NHLBD [E]" nih.gov>, "Panepinto, Julie (NIH/NHLBI [E]" ih.gov>, "Fauci, Anthony (NIH/NIAID) [E]" [@niaid.nih.gov> Ce: "Tabak, Lawrence (NIH/OD) [E]" HE 2b. 20v>, "Schwetz, Tara (NIH/OD) (EL" nih.gov>, "Auchincloss, Hugh (NIH/NIAID) [E]" jniaid.nih.gov>, "Harper, Jill (NIH/NIAID) [E]" niaid.nih.gov> Subject: RE: Seeing Bill Gates tomorrow Date: Tue, 27 Sep 2022 17:42:36 -0400 Importance: Normal Thanks, Carl. Is the anti-HIV CRISPR trial targeting CCR5 or integrated proviruses? Francis From: Dieffenbach, Carl (NIH/NIAID) [E] [EEO niaid.nih.gov> Sent: Tuesday, September 27, 2022 9:58 AM To: Collins, Francis (NIH/NHGRI) [E] nih.gov>; Gibbons, Gary (NIH/NHLBI) [E] Panepinto, Julie (NIH/NHLBI) [E] nih.gov>; Fauci, Anthony (NIH/NIAID) [E] Ce: Tabak, Lawrence (NIH/OD) [E] nih.gov>; Schwetz, Tara (NIH/OD) [E] Auchincloss, Hugh (NIH/NIAID) [E] niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] Subject: RE: Seeing Bill Gates tomorrow niaid.nih.gov> nih.gov>; niaid.nih.gov> Francis, We have continued to meet with Mike and his team. One of his team members is coming for a visit in October so we can have a face to face deep dive. Since Sunnylands the Temple group initiated the phase one of a anti-HIV CRISPR trial in Philadelphia, part of the NIAID Collaboratory. We have reviewed a set of grants looking new and improved delivery systems for gene therapies. We plan to fund 3-4 and the details will be announced in the new fiscal year. We are expanding in 2023 the process for sites in LMICs to apply for assistance to support cure trials including but not limited to gene-based technologies. The first iteration of this strategy has been completed, now on to version 2.0. Last, the plans for an bNAb treatment and cure trial in Africa with BMGF is moving forward. Waiting for BMGF to finish production of the bNAbs. This continues to be parallel and complementary activities with BMGF. Best regards, Carl From: Collins, Francis (NIH/NHGRI) [E] [EO nih.gov> Sent: Tuesday, September 27, 2022 6:48 AM To: Gibbons, Gary (NIH/NHLBI) [E] nih.gov>; Panepinto, Julie (NIH/NHLBI) [E] nih.gov>; Dieffenbach, Carl (NIH/NIAID) [E] niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] niaid.nih.gov> Cc: Tabak, Lawrence (NIH/OD) [E] nih.gov>; Schwetz, Tara (NIH/OD) [E] nih.gov> Subject: Seeing Bill Gates tomorrow Hi all,

This is our OCR of the page, with running headers and footers removed. The Committee's PDF is authoritative; quote from it. Machine-readable, including the uncleaned text: /api/page/gates/865

Records on this page

RecordDateTypePages
gates:email:00753 2022-09-27 email 865–866
RE: Seeing Bill Gates tomorrow 2022-09-27 email 865